RIGL : Analysis & Opinions

  1. Rigel Tanks After Late-Stage Drug Failure (RIGL)

    October 21, 2016
    Rigel Pharmaceuticals stock got hammered October 20 after its bleeding disorder drug, fostamatinib, failed in a Phase 3 trial.
Trading Center